Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 520

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity

Open access
Saal, Lao H., Johansson, Peter, Holm, Karolina, Gruvberger-Saal, Sofia K., She, Qing-Bai, Maurer, Matthew, Koujak, Susan, Ferrando, Adolfo A., Malmström, Per, Memeo, Lorenzo, Isola, Jorma, Bendahl, Pär-Ola, Rosen, Neal, Hibshoosh, Hanina, Ringnér, Markus, Borg, Åke, Parsons, Ramon·2007·Proceedings of the National Academy of Sciences

Abstract

Pathway-specific therapy is the future of cancer management. The oncogenic phosphatidylinositol 3-kinase (PI3K) pathway is frequently activated in solid tumors; however, currently, no reliable test for PI3K pathway activation exists for human tumors. Taking advantage of the observation that loss of PTEN, the negative regulator of PI3K, results in robust activation of this pathway, we developed and validated a microarray gene expression signature for immunohistochemistry (IHC)-detectable PTEN loss in breast cancer (BC). The most significant signature gene was PTEN itself, indicating that PTEN mRNA levels are the primary determinant of PTEN protein levels in BC. Some PTEN IHC-positive BCs exhibited the signature of PTEN loss, which was associated to moderately reduced PTEN mRNA levels cooperating with specific types of PIK3CA mutations and/or amplification of HER2 . This demonstrates that the signature is more sensitive than PTEN IHC for identifying tumors with pathway activation. In independent data sets of breast, prostate, and bladder carcinoma, prediction of pathway activity by the signature correlated significantly to poor patient outcome. Stathmin, encoded by the signature gene STMN1 , was an accurate IHC marker of the signature and had prognostic significance in BC. Stathmin was also pathway-pharmacodynamic in vitro and in vivo . Thus, the signature or its components such as stathmin may be clinically useful tests for stratification of patients for anti-PI3K pathway therapy and monitoring therapeutic efficacy. This study indicates that aberrant PI3K pathway signaling is strongly associated with metastasis and poor survival across carcinoma types, highlighting the enormous potential impact on patient survival that pathway inhibition could achieve.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0702507104

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 520

Metadata

Authors
Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., Isola, J., Bendahl, P.-O., Rosen, N., Hibshoosh, H., Ringnér, M., Borg, Å., & Parsons, R.
Venue
Proceedings of the National Academy of Sciences
Published
2007-05
Volume
104
Issue
18
Pages
7564-7569
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2128613144
Cited by
520
References
7
FWCI
15.09
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. https://app.cochat.ai/papers/10.1073/pnas.0702507104
The paper
Saal, L. H., Johansson, P., Holm, K., Gruvberger-Saal, S. K., She, Q.-B., Maurer, M., Koujak, S., Ferrando, A. A., Malmström, P., Memeo, L., Isola, J., Bendahl, P.-O., Rosen, N., Hibshoosh, H., Ringnér, M., Borg, Å., & Parsons, R. (2007). Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0702507104

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.